What is the clinical evidence from this study?

Study design: Observational. Population: Atrial fibrillation and multimorbidity (n=192716). Intervention: Potentially clinically significant drug-drug interactions (≥ 1 DDI) vs. No potentially clinically significant drug-drug interactions. Primary outcome: Cardiovascular death (HR 1.28, 95% CI 1.24-1.32).

What does this research mean for the field?

Having at least one potentially clinically significant drug-drug interaction is associated with a 28% higher hazard of cardiovascular death in older adults with atrial fibrillation and multimorbidity. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 14, 2026Open Access

Potentially Clinically Significant Drug-Drug Interactions in Older Adults with Atrial Fibrillation and Multimorbidity: Prevalence, Correlates, and Association with Adverse Clinical Outcomes in a Swedish National Register-Based Study

Key Result

Having at least one potentially clinically significant drug-drug interaction was associated with a 28% higher hazard of cardiovascular death (HR 1.28) in older adults with atrial fibrillation.

Key Points

This research aims to assess the prevalence and correlates of clinically significant drug-drug interactions (DDIs) in older adults with atrial fibrillation and multimorbidity.
Analyzed data from a national register in Sweden
Focused on older adults diagnosed with atrial fibrillation
Identified and classified potentially significant drug-drug interactions
Found a high prevalence of clinically significant drug-drug interactions
Established a correlation between drug-drug interactions and adverse clinical outcomes
Identified specific high-risk groups for potential DDIs

Study Design

Type

Observational (n=192,716)

Structured PICO

Does exposure to potentially clinically significant drug-drug interactions increase the risk of adverse clinical outcomes in older adults with atrial fibrillation and multimorbidity?

Population

192,716 adults aged 65 years or older (median age 79.6, 54.5% male) with atrial fibrillation, ≥1 comorbidity, and prescribed ≥2 medications at baseline, derived from Swedish national health registers.

Intervention

Exposure to potentially clinically significant drug-drug interactions (DDIs), defined by an explicit international consensus list of 72 DDIs.

Comparator

No exposure to potentially clinically significant drug-drug interactions.

Outcome

All-cause and cardiovascular (CV) mortality, all-cause and CV hospitalisation, stroke, bleeding, and injurious falls assessed independently over a two-year follow-up.hard clinical

Potentially clinically significant drug-drug interactions are highly prevalent (37.5%) in older adults with atrial fibrillation and multimorbidity, and are associated with an increased hazard of all-cause and cardiovascular mortality.

Main Result

Effect estimate: HR 1.28 (95% CI 1.24-1.32)

Absolute Event Rate: 7.3% vs 4.19%

Limitations

Did not account for drug-disease or drug-food interactions
Unable to include established risk scores for stroke and bleeding
Residual confounding by indication
Unable to adjust for clinical complexity beyond polypharmacy
Not adjusting for AF subtype in the Cox regression analyses
Disease duration and long-term medication history not accounted for

Abstract

Potentially clinically significant DDIs were prevalent in older adults with AF and multimorbidity, with adverse clinical implications. Identifying these high-risk groups is essential for preventive strategies and effective clinical management.

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Amrouch et al. (Qui,) realizaram um estudo observacional em fibrilação atrial e multimorbidade (n=192.716). Interações fármaco-fármaco potencialmente clinicamente significativas (≥ 1 DDI) vs. Sem interações fármaco-fármaco potencialmente clinicamente significativas foram avaliadas em relação à morte cardiovascular (HR 1,28, IC 95% 1,24-1,32). Ter pelo menos uma interação fármaco-fármaco potencialmente clinicamente significativa estava associado a um risco 28% maior de morte cardiovascular (HR 1,28) em adultos mais velhos com fibrilação atrial.

synapsesocial.com/papers/699010ce2ccff479cfe56f88 https://doi.org/https://doi.org/10.1007/s10557-025-07825-8